Nkgen Biotech Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nkgen Biotech Inc 's ROA in the first quarter of 2025?
Nkgen Biotech Inc achieved a return on average assets (ROA) of 108.74 % in its first quarter of 2025 a new company high.

ROA has improved compared to -120.48% in the fourth quarter of 2024, due to net income growth.

However, within the Healthcare sector 7 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 48, from total ROA ranking in the fourth quarter of 2024 at 5310.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	-2.91 %	-1.52 %	-40.49 %	-75.19 %	-90.69 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	17	-19	-73	-119	-95
Return On Assets (TTM)	108.74 %	-120.48 %	-458.3 %	-646.69 %	-312.98 %
NKGN's Total Ranking	# 48	# 5310	# 5007	# 5097	# 5063
Total Assets (TTM) in million	16	16	15	16	16
Seq. Total Assets Change	-2.4 %	8.24 %	-4.17 %	-4.09 %	-1 %
Seq. Net Income Change	476.09 %	-59.62 %	-	-	-

NKGN's 5 Years Annual ROA >> Back to NKGN Management Effectiveness >> Compare NKGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 1
Sector	# 8
Overall	# 44

Return On Assets Statistics
High	Average	Low
108.74 %	-119.62 %	-646.69 %
(Mar 31 2025)		(Jun 30 2024)

News about Nkgen Biotech Inc Return on Assets ROA

Navigating Promise and Peril NKGen Biotechs Dual Journey in FTD Treatment Innovation and Financial Realignment,

Emerging Therapeutic Frontier: NKGen Biotech s Innovative Step Forward in Frontotemporal Dementia Treatment Amid Financial Challenges NKGen Biotech Inc. a company immersed in the cutting-edge landscape of biotechnology, has taken a meaningful stride in the pursuit of emerging therapeutic solutions with the announcement of the first dose administration of Troculeucel to a frontotemporal dementia (FTD) patient under the FDA-cleared compassionate use program. This is a pivotal step for patients who have limited treatment avenues, highlighting the company s commitment to addressing unmet needs within the medical community. A Step Towards Hope for FTD Patients Frontotemporal dementia is a devastating condition characterized by progressive neuronal loss, and it remains a major therapeutic challenge with limited effective treatments available. The administration of Troculeucel, NKGen s innovative therapeutic candidate, signifies a potential breakthrough in offering hope to those afflicted with this debilitating disease.

Evolving Treatment NKGen Biotechs Promising Advances in Alzheimers and Solid Tumor Therapies

Recent developments from NKGen Biotech highlight significant strides in the treatment of two major health challenges: moderate Alzheimer s disease (AD) and advanced solid tumors. The company s innovative approach, leveraging natural killer (NK) cell therapies, stands out in an increasingly competitive biotech landscape. With pivotal Phase 1 clinical data indicating potential breakthroughs, the implications for patients and the company s future are profound. Phase 1 Clinical Data in Alzheimer s Disease NKGen Biotech recently announced positive outcomes from its Phase 1 clinical trials, specifically for its product Troculeucel, aimed at treating moderate Alzheimer s disease. In a cohort of three patients receiving the highest dosage of 6 billion cells per treatment, two individuals exhibited notable improvements in their Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. Remarkably, this improvement reflected a clinical upgrade from moderate to mild Alzheimer s disease within just three months of treatment. This early success is critical, as traditional therapies for Alzheimer s have faced hurdles in efficacy and safety. These promising results position NKGen as a trailblazer in the race toward effective treatments for neurodegenerative diseases. The transition to Phase 2 is a crucial step, suggesting that the company is confident in the sustainability of these results and is ready to expand its patient population in hopes of statistically validating these findings.

Financial Statements
Nkgen Biotech Inc 's Assets	$ 16 million	NKGN's Balance sheet
Nkgen Biotech Inc 's Income	$ 31 million	Quarterly NKGN's Income Statement
NKGN's Income by Division		See NKGN's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	-1.52 %	-90.55 %	0.1 %	-	-
Total Assets in million	16	16	174	174	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	-83	5	-1	0
Annual Return On Assets	-0.33 %	-503.33 %	2.61 %	-0.57 %	-

NKGN's 5 Years Annual ROA >> Back to NKGN Management Effectiveness >> Compare NKGN ROA to its Competitors

More Return On Assets Ratios
NKGN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NKGN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NKGN's Competitors
Subscribers only: Roa for Nkgen Biotech Inc 's Suppliers
Subscribers only: Return On Assets for NKGN's Customers

You may also want to know
NKGN's Roi	NKGN's Inventory Turnover Ratio	NKGN's Growth Rates	NKGN's Dividend Comparisons
	NKGN's Profitability Ratios	NKGN's Asset Turnover Ratio	NKGN's Dividend Growth
NKGN's Roe	NKGN's Valuation Ratios	NKGN's Financial Strength Ratios	NKGN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector	ROA
Pavmed Inc	170.91 %
Capforce Inc	154.60 %
Nkgen Biotech Inc	108.74 %
Camp4 Therapeutics Corporation	99.51 %
Semnur Pharmaceuticals Inc	97.62 %
Alumis inc	92.46 %
Oak Woods Acquisition Corp	87.29 %
Tao Synergies Inc	70.91 %
Outlook Therapeutics Inc	68.23 %
Earth Science Tech Inc	62.66 %
Avalo Therapeutics Inc	58.88 %
Interpace Biosciences Inc	56.00 %
Exelixis Inc	51.45 %
Stablecoin Development Corporation	50.36 %
Synlogic Inc	47.83 %
Adma Biologics Inc	46.83 %
Agios Pharmaceuticals Inc	46.06 %
Pharmacyte Biotech Inc	44.19 %
Gridai Technologies Corp	43.94 %
Medinotec Inc	40.68 %
Sbc Medical Group Holdings Incorporated	40.28 %
Dariohealth Corp	38.41 %
Seres Therapeutics Inc	36.27 %
Longduoduo Co Ltd	34.93 %
Edwards Lifesciences Corporation	33.98 %
Cytomx Therapeutics Inc	32.17 %
Bluebird Bio Inc	31.57 %
Novavax inc	29.99 %
Ptc Therapeutics inc	29.31 %
Nutriband Inc	27.24 %

Date modified: 2026-09-26T07:39:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.